GT Biopharma Inc. (GTBP)
GTBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/0001654954-21-004295-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GTBP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000109657 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$28.3M |
| Operating income | -$6.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $5.3M |
| Total assets | $5.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $5.0M cash; operating cash flow -$3.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,804,380 (2026-08-10); 3,557,502 a year earlier; 40,639,688 three years earlier. 3y figure adjusted for splits (1-for-30 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 2; latest 1-for-25 on 2026-09-08 | Source 2026-09-08 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-05-22 |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.5M | -$4.3M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$2.8M | -$2.5M | $8.9M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$5.7M | -$4.0M | $6.8M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | Not filed | $8.3M | -$3.7M | $2.5M | No debt tags | Needs four quarters | 10-Q/A 2026-03-06 |
| Q2 2025 2025-06-30 | Not filed | -$30.2M | -$3.0M | $5.2M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$776K | -$2.2M | $2.4M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$3.8M | -$2.5M | $4.0M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
| Q3 2024 2024-09-30 | Not filed | -$3.4M | -$2.7M | $6.4M | No debt tags | Needs four quarters | 10-Q/A 2026-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-20 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-10-13 |
Source: SEC EDGAR submissions feed, 885 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.8% |
| 1 month | -42.8% |
| 3 months | -49.9% |
| Year to date | +373.9% |
| 1 year | +409.6% |
| From 52-week high | -81.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CURX | Curanex Pharmaceuticals Inc | $4.63 | -0.11% | $7.3M |
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| MBRX | Moleculin Biotech Inc. | $7.14 | -9.28% | $7.6M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier